Surgery for pancreatic neuroendocrine tumors during the COVID-19 pandemic: a retrospective cohort from a high-volume center - Takeaways - MDSpire

Surgery for pancreatic neuroendocrine tumors during the COVID-19 pandemic: a retrospective cohort from a high-volume center

  • By

  • Salvatore Paiella

  • Luca Landoni

  • Matteo De Pastena

  • Giovanni Elio

  • Fabio Casciani

  • Sara Cingarlini

  • Mirko D’Onofrio

  • Giulia Maistri

  • Ivan Ciatti

  • Massimiliano Tuveri

  • Maria Vittoria Davì

  • Claudio Luchini

  • Katia Donadello

  • Gessica Manzini

  • Giuseppe Malleo

  • Roberto Salvia

  • July 21, 2024

  • 0 min

Share

  • 1

    The COVID-19 pandemic significantly disrupted cancer care in Italy, leading to postponed surgeries and increased waiting times for patients with pancreatic neuroendocrine tumors.

  • 2

    During the pandemic, the median time from diagnosis to surgery for NF-PNETs increased from 182 to 382 days, highlighting delays in treatment.

  • 3

    A higher frequency of preoperative oncological treatments was observed during the COVID-19 era, indicating a shift in management strategies.

  • 4

    Patients diagnosed during the pandemic showed increased prevalence of suspected vascular infiltration and metastatic lymphadenopathies compared to the pre-pandemic period.

  • 5

    Despite longer waiting times, major postoperative complications were less frequent during the COVID-19 period, suggesting potential changes in surgical outcomes.

Original Source(s)

Related Content